指南与共识胸部肿瘤放疗放疗物理与技术

优化立体定向心律失常放射消融(STAR)中的关键结构勾画:STOPSTORM.eu 联盟的基准结果与共识指南

Refining critical structure contouring in STereotactic Arrhythmia Radioablation (STAR): Benchmark results and consensus guidelines from the STOPSTORM.eu consortium.
指南 / 共识 · Radiother Oncol · 2023-10-10

STOPSTORM.eu 联盟要求 20 个中心在 3 例 STAR 病例中勾画 31 个危及器官(OAR),经专家 panel 审核、专题研讨会反馈与认证后制定共识指南。肺部中位 DSC 为 0.96,心脏瓣膜中位 DSC 为 0.16,心脏亚结构勾画差异较大,可能影响 STAR 治疗计划与剂量学评估。

要点

  • 肺部中位 DSC 为 0.96,主动脉中位 DSC 为 0.90,标准放疗 OAR 勾画一致性高。
  • 心脏瓣膜中位 DSC 为 0.16,冠状动脉中位 DSC 为 0.4,心脏亚结构勾画差异较大。
  • 研讨会后所有中心获认证,并建立 STAR 关键结构勾画共识指南。

核心结论

  • STOPSTORM 多中心关键结构勾画基准研究显示标准放疗 OAR 一致性高,但心脏亚结构勾画差异较大,可能显著影响 STAR 治疗计划与剂量学评估。
  • 为标准化 OAR 勾画,建立了 STAR 关键结构勾画共识指南。

研究设计与样本

  • STOPSTORM.eu 联盟内中心被要求在 3 例 STAR 病例中勾画 31 个 OAR,勾画由联盟专家 panel 审核。
  • 经专题研讨会反馈与认证后,计算 DSC、MDA 和 HD95 进行定量分析,共 20 个中心参与。

主要发现

  • 肺部中位 DSC=0.96、中位 MDA=0.1 mm、中位 HD95=1.1 mm;主动脉中位 DSC=0.90、中位 MDA=0.1 mm、中位 HD95=1.5 mm。
  • 部分中心未纳入胃食管交界,导致胃和食管勾画差异。
  • 心脏腔室中位 DSC=0.83、中位 MDA=0.2 mm、中位 HD95=0.5 mm;瓣膜中位 DSC=0.16、中位 MDA=4.6 mm、中位 HD95=16.0 mm。
  • 冠状动脉中位 DSC=0.4、中位 MDA=0.7 mm、中位 HD95=8.3 mm;窦房结和房室结中位 DSC=0.29、中位 MDA=4.4 mm、中位 HD95=11.4 mm。

关键数值与推荐

  • 肺部中位 DSC=0.96、中位 MDA=0.1 mm、中位 HD95=1.1 mm。
  • 主动脉中位 DSC=0.90、中位 MDA=0.1 mm、中位 HD95=1.5 mm。
  • 心脏腔室中位 DSC=0.83、中位 MDA=0.2 mm、中位 HD95=0.5 mm。
  • 心脏瓣膜中位 DSC=0.16、中位 MDA=4.6 mm、中位 HD95=16.0 mm。
  • 冠状动脉中位 DSC=0.4、中位 MDA=0.7 mm、中位 HD95=8.3 mm;窦房结和房室结中位 DSC=0.29、中位 MDA=4.4 mm、中位 HD95=11.4 mm。

临床怎么用

  • 研讨会后所有中心均获认证,STAR 关键结构勾画共识指南已建立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In patients with recurrent ventricular tachycardia (VT), STereotactic Arrhythmia Radioablation (STAR) shows promising results. The STOPSTORM.eu consortium was established to investigate and harmonise STAR treatment in Europe. The primary goals of this benchmark study were to standardise contouring of organs at risk (OAR) for STAR, including detailed substructures of the heart, and accredit each participating centre. MATERIALS AND METHODS: Centres within the STOPSTORM.eu consortium were asked to delineate 31 OAR in three STAR cases. Delineation was reviewed by the consortium expert panel and after a dedicated workshop feedback and accreditation was provided to all participants. Further quantitative analysis was performed by calculating DICE similarity coefficients (DSC), median distance to agreement (MDA), and 95th percentile distance to agreement (HD95). RESULTS: Twenty centres participated in this study. Based on DSC, MDA and HD95, the delineations of well-known OAR in radiotherapy were similar, such as lungs (median DSC = 0.96, median MDA = 0.1 mm and median HD95 = 1.1 mm) and aorta (median DSC = 0.90, median MDA = 0.1 mm and median HD95 = 1.5 mm). Some centres did not include the gastro-oesophageal junction, leading to differences in stomach and oesophagus delineations. For cardiac substructures, such as chambers (median DSC = 0.83, median MDA = 0.2 mm and median HD95 = 0.5 mm), valves (median DSC = 0.16, median MDA = 4.6 mm and median HD95 = 16.0 mm), coronary arteries (median DSC = 0.4, median MDA = 0.7 mm and median HD95 = 8.3 mm) and the sinoatrial and atrioventricular nodes (median DSC = 0.29, median MDA = 4.4 mm and median HD95 = 11.4 mm), deviations between centres occurred more frequently. After the dedicated workshop all centres were accredited and contouring consensus guidelines for STAR were established. CONCLUSION: This STOPSTORM multi-centre critical structure contouring benchmark study showed high agreement for standard radiotherapy OAR. However, for cardiac substructures larger disagreement in contouring occurred, which may have significant impact on STAR treatment planning and dosimetry evaluation. To standardize OAR contouring, consensus guidelines for critical structure contouring in STAR were established.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Balgobind BV, Visser J, Grehn M, et al. Refining critical structure contouring in STereotactic Arrhythmia Radioablation (STAR): Benchmark results and consensus guidelines from the STOPSTORM.eu consortium. Radiother Oncol. 2023. PMID: 37827279. doi:10.1016/j.radonc.2023.109949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。